Bausch Health Companies BHC Solta Medical — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bausch Health Companies's solta medical — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bausch Health Companies's solta medical — R&D?
- Bausch Health Companies (BHC) reported solta medical — R&D of $8M in Q1 2026.
- How has Bausch Health Companies's solta medical — R&D changed year-over-year?
- Bausch Health Companies's solta medical — R&D increased by 60.0% year-over-year, from $5M to $8M.
- What is the long-term trend for Bausch Health Companies's solta medical — R&D?
- Over 3 years (2022 to 2025), Bausch Health Companies's solta medical — R&D has grown at a 11.0% compound annual growth rate (CAGR), from $19M to $26M.
- What does solta medical — R&D mean?
- Represents the costs associated with the discovery, development, and clinical testing of new products or enhancements within the Solta Medical segment. This investment is critical for maintaining long-term competitiveness and innovation in the medical device market.